The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000

Philip J. Turner, J. M. Greenhalgh, H. Kurt, H. Eraksoy, R. Ozturk, A. Basustaoglu, V. Korten, S. Unal, S. Ulusoy, A. Yuce, Y. Taoova, J. Verhaegen, G. Verschraegen, P. de Mol, G. Glupczynski, M. Delmee, S. Lauwers, M. Struelens, R. Masterton, J. HoodA. Bint, P. Chadwick, R. Holliman, U. Riley, R. A. Swann, E. Priztbuer, R. Thomssen, A. Rodloff, J. Heesemann, H. Hahn, K. P. Schaal, E. Giacobone, R. Fontana, B. Markova, E. Chemelerova, D. Dzierzanowska, S. V. Resvan, P. Larsson, J. Bille

Research output: Contribution to journalArticlepeer-review

Abstract

In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated rom serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. Iwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.

Original languageEnglish
Pages (from-to)563-567
Number of pages5
JournalClinical Microbiology and Infection
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Keywords

  • Acinetobacter
  • Antibiotics
  • Carbapenems
  • Meropenem
  • MYSTIC

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Fingerprint Dive into the research topics of 'The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000'. Together they form a unique fingerprint.

Cite this